Streetbeat News

Analyst Ratings

TSX:STN

RBC Capital analyst Sabahat Khan maintains an Outperform rating on Stantec (TSX:STN) and raises the price target from C$89 to C$96.

Portfolio Pulse from richadhand@benzinga.com

August 11, 2023 | 3:11 pm

CRC

Stifel analyst Derrick Whitfield has maintained a 'Buy' rating on California Resources (NYSE:CRC) and raised the price target from $55 to $60.

Portfolio Pulse from Benzinga Newsdesk

August 11, 2023 | 3:10 pm

TSX:QBR

RBC Capital analyst Drew McReynolds has maintained a 'Sector Perform' rating on Quebecor (TSX:QBR) and raised the price target from C$36 to C$38.

Portfolio Pulse from richadhand@benzinga.com

August 11, 2023 | 3:10 pm

CPA

TD Cowen analyst Helane Becker maintains an Outperform rating on Copa Holdings (NYSE:CPA) but lowers the price target from $130 to $125.

Portfolio Pulse from Benzinga Newsdesk

August 11, 2023 | 3:09 pm

TSX:ONEX

RBC Capital analyst Geoffrey Kwan maintains a 'Sector Perform' rating on Onex (TSX:ONEX) and raises the price target from C$87 to C$103.

Portfolio Pulse from richadhand@benzinga.com

August 11, 2023 | 3:09 pm

TSX:DR

RBC Capital analyst Douglas Miehm maintains a Sector Perform rating on Medical Facilities (TSX:DR) and raises the price target from C$10 to C$11.

Portfolio Pulse from richadhand@benzinga.com

August 11, 2023 | 3:08 pm

RL

TD Cowen analyst John Kernan maintains an Outperform rating on Ralph Lauren (NYSE:RL) but lowers the price target from $150 to $142.

Portfolio Pulse from Benzinga Newsdesk

August 11, 2023 | 3:08 pm

TSX:KXS

RBC Capital analyst Paul Treiber has reiterated an 'Outperform' rating on Kinaxis (TSX:KXS) and maintained a price target of C$220.

Portfolio Pulse from richadhand@benzinga.com

August 11, 2023 | 3:07 pm

TSX:KMP

RBC Capital analyst Pammi Bir maintains an Outperform rating on Killam Apartment Real Est (TSX:KMP) and raises the price target from C$23 to C$23.5.

Portfolio Pulse from richadhand@benzinga.com

August 11, 2023 | 3:06 pm

NBY

Ladenburg Thalmann has maintained its 'Buy' rating on NovaBay Pharmaceuticals (AMEX:NBY) but has lowered the price target from $6 to $3.8.

Portfolio Pulse from Benzinga Newsdesk

August 11, 2023 | 3:06 pm